[1] 杨柳,郝红晓,孙芳芳,等.乙型肝炎病毒感染与免疫[J].中华实验和临床病毒学杂志,2021,35(3):322-327. [2] 徐京杭,于岩岩,徐小元.肝硬化研究进展和展望[J].中华肝脏病杂志,2021,29(2):108-110. [3] 倪盟,曾雷.miRNA单核苷酸多态性与HBV感染相关疾病关系的研究进展[J].吉林大学学报(医学版),2021,47(6):1588-1593. [4] 林燕君,林烨鸿,周卿,等.白细胞介素-6单核苷酸多态性与乙型病毒性肝炎肝硬化的相关性[J].中国临床药理学杂志,2020,36(2):110-113. [5] 黎增辉,李金强,谢雅,等.IL-17基因多态性与HBV感染致肝硬化病情和临床转归的关系[J].中华医院感染学杂志,2021,31(11):1607-1611. [6] PENG L J,GUO J S,ZHANG Z,et al.Polymorphisms of AZIN1 rs2679757 and TRPM5 rs886277 are associated with cirrhosis risk in Chinese patients with chronic hepatitis B[J].Infect Int Electron Ed,2012,1(2):103-109. [7] RESINO S,FERNÁNDEZ-RODRÍGUEZ A,PINEDA-TENOR D,et al.TRPM5 rs886277 polymorphism predicts hepatic fibrosis progression in non-cirrhotic HCV-infected patients[J].J Clin Med,2021,10(3):483. [8] PINEDA-TENOR D,GÓMEZ-MORENO A Z,SÁNCHEZ-RUANO J J,et al. MTHFR rs1801133 polymorphism is associated with liver fibrosis progression in chronic hepatitis C:a retrospective study[J].Front Med,2020,7:582666. [9] JIMÉNEZ-SOUSA,GÓMEZ-MORENO,PINEDA-TENOR,et al.Impact of DARC rs12075 variants on liver fibrosis progression in patients with chronic hepatitis C:a retrospective study[J].Biomolecules,2019,9(4):143. [10] LIU F,LUO L M,WEI Y G,et al.Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population[J].Gene,2015,564(1):14-20. [11] LI Q Y,YANG X,GUO Z Z.Correlation Analysis of Cytochrome P450 SNPs in Hepatitis B-Caused Cirrhosis Patients[J].Biomed Res Int,2022,9891184. [12] NEPOMNYASHCHIKH D L,VAVILIN V A,AIDAGULOVA S V,et al.Cytochrome P450 2D6 polymorphism is a molecular genetic marker of liver cirrhosis progression[J].Bull Exp Biol Med,2012,152(5):633-636. [13] ABO-HASHEM E M,EL-EMSHATY W M,EL SAYED FARAG R,et al.Genetic polymorphisms of cytochrome P4501A1 (CYP1A1) and glutathione S-transferase P1 (GSTP1) and risk of hepatocellular carcinoma among chronic hepatitis C patients in Egypt[J].Biochem Genet,2016,54(5):696-713. [14] 陈玮钰,舒发明,王涵,等.细胞色素P450家族在肝脏代谢相关疾病中的作用[J].临床肝胆病杂志,2022,38(9):2182-2187. [15] LIU J,LU Y F,CORTON J C,et al.Expression of cytochrome P450 isozyme transcripts and activities in human livers[J].Xenobiotica,2021,51(3):279-286. [16] GUO L Y,DU Y,QU S S,et al.rVarBase:an updated database for regulatory features of human variants[J].Nucleic Acids Res,2016,44(D1):D888-D893. [17] STIPP M C,ACCO A.Involvement of cytochrome P450 enzymes in inflammation and cancer:a review[J].Cancer Chemother Pharmacol,2021,87(3):295-309. [18] BURLAKA A P,VIRKO S V,BURLAKA A A,et al.Cytochrome P450 content in primary tumors and liver metastases of patients with metastatic colorectal cancer[J].Exp Oncol,2020,42(4):330-332. [19] SHARZEHAN M A K,SITO H,ABDULLAH N,et al.Association between CYP2E1 polymorphisms and colorectal cancer risk:a systematic review and meta-analysis[J].Sci Rep,2022,12:20149. [20] CHAN C W H,LI C X,XIAO E J,et al.Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy:a systematic review and meta-analysis[J].Expert Rev Mol Med,2022,24:e1. [21] LUO B,YAN D D,YAN H L,et al.Cytochrome P450:Implications for human breast cancer (Review)[J].Oncol Lett,2021,22:548. [22] HO M T,KELLY E J,BODOR M,et al.Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects[J].Ann Hepatol,2011,10(3):327-332. [23] 孙可望,黄象艳.献血者隐匿性乙肝病毒感染的研究进展[J].中华实验和临床病毒学杂志,2022,36(6):753-757. [24] 向涛,袁观斗,吕军,等.肝纤维化动物模型研究进展与评价[J].中华实验外科杂志,2023,40(3):591-594. |